AbCellera Biologics Inc. Common Shares Earnings Dividend

AbCellera Biologics Inc. Common Shares’s revenue fell -76.29% since last year same period to $4.05Mn in the Q2 2026. On a quarterly growth basis, AbCellera Biologics Inc. Common Shares has generated -51.29% fall in its revenue since last 3-months.

AbCellera Biologics Inc. Common Shares’s net profit fell -59.61% since last year same period to $-55.43Mn in the Q2 2026. On a quarterly growth basis, AbCellera Biologics Inc. Common Shares has generated -28.41% fall in its net profits since last 3-months.

AbCellera Biologics Inc. Common Shares’s net profit margin fell -573.27% since last year same period to -1368.57% in the Q2 2026. On a quarterly growth basis, AbCellera Biologics Inc. Common Shares has generated -163.63% fall in its net profit margins since last 3-months.

AbCellera Biologics Inc. Common Shares’s earning per share (EPS) estimates for the current quarter stand at -0.17 - a 15% jump from last quarter’s estimates.

AbCellera Biologics Inc. Common Shares’s earning per share (EPS) estimates for the current year stand at -0.17.

AbCellera Biologics Inc. Common Shares’s earning per share (EPS) fell -50% since last year same period to -0.18 in the Q2 2026. This indicates that the AbCellera Biologics Inc. Common Shares has generated -50% annual rate of fall in its earning per share (EPS) in the last 4 quarters.